Are nilotinib-associated vascular adverse events an under-estimated problem? - Wikidata - awgldk - TriplyDB

Are nilotinib-associated vascular adverse events an under-estimated problem?

Are nilotinib-associated vascular adverse events an under-estimated problem?

http://www.wikidata.org/entity/Q41530191

about

Nilotinib - Differentiating the Hope from the Hype.

P2860

Q38840128-4C040A47-3639-424E-A4FC-CB4B28E86386

P2860

Are nilotinib-associated vascular adverse events an under-estimated problem?

http://www.wikidata.org/entity/Q41530191

description

2015 nî lūn-bûn

@nan

2015年の論文

@ja

2015年論文

@yue

2015年論文

@zh-hant

2015年論文

@zh-hk

2015年論文

@zh-mo

2015年論文

@zh-tw

2015年论文

@wuu

2015年论文

@zh

2015年论文

@zh-cn

name

Are nilotinib-associated vascular adverse events an under-estimated problem?

@en

type

label

Are nilotinib-associated vascular adverse events an under-estimated problem?

@en

prefLabel

Are nilotinib-associated vascular adverse events an under-estimated problem?

@en

P1433

Q41530191-BBC93F02-9A43-4F11-8BF9-CED89E0D9C92

P1476

Q41530191-39E67C09-2224-46BD-B94B-63B5563AEE70

P2093

Q41530191-2FE59CBF-E65A-4166-AD7E-40D3452A6833

Q41530191-46B7A05D-21DF-47A2-BEF4-FF39A79DF56E

Q41530191-4A2709FB-A56E-4B1C-9ADB-971B47CE97BC

Q41530191-7721BB19-E917-4988-B0CD-E0AED1CC2633

Q41530191-93900FAB-00E7-43CF-84D4-3DA4D32BE7BC

Q41530191-B00332FF-1D51-48CD-8730-4425661C5AD4

Q41530191-D9A87CD3-632E-4C91-8FB5-91A0042A2D12

Q41530191-DE536311-A309-4DA9-8D28-277AD99AAF5D

Q41530191-F03E4884-D531-495E-B81E-70C64695E0DF

P2860

Q41530191-0350439B-44DF-4B35-980B-EC3EF2C1FD92

Q41530191-3059627A-E8BD-47D1-AD5E-F21C2BA50539

Q41530191-39E1DCBA-5454-4ABF-BB78-2006D734F5C9

Q41530191-46B65C52-2168-462F-8C9F-6FEC5E2DF88B

Q41530191-52A68992-FBDB-4109-B3B7-196E911409CA

Q41530191-9D652861-16DB-4D31-A1E6-8753AD47CBEB

Q41530191-A51CB733-B9F0-4B10-9875-9042BE075336

Q41530191-A6BB52DA-272D-4139-9075-4454CDCAC6BE

Q41530191-AD1C63C1-7B2D-4102-9E6C-3A5EB4D95B14

Q41530191-C470645F-7C88-4120-A71F-0249DBE4D638

P304

Q41530191-2B968B30-4628-4D47-B31B-2D770D985F7E

P31

Q41530191-EA8FA2D8-AAC5-45A0-B3D4-5C4D31AA8436

P356

Q41530191-A692C951-F09A-419D-A7D9-AD108600CD7A

P433

Q41530191-594A34F9-303C-471E-BBC3-DFF79BB72752

P478

Q41530191-53554598-48C8-42FC-9C06-90E1154CCEDF

P577

Q41530191-B4181DF7-765A-4B1F-84A7-00413E4D1F1A

P698

Q41530191-9DC310A2-EC47-444B-8280-0B705ADD6796

P356

P1433

Fundamental and Clinical Pharmacology

P1476

Are nilotinib-associated vascular adverse events an under-estimated problem?

@en

P2093

Anne Spreux

http://www.w3.org/2001/XMLSchema#string

Antoine Thyss

http://www.w3.org/2001/XMLSchema#string

Bernadette Baldin

http://www.w3.org/2001/XMLSchema#string

Daniel Re

http://www.w3.org/2001/XMLSchema#string

Fanny Rocher

http://www.w3.org/2001/XMLSchema#string

Florian Ajmia

http://www.w3.org/2001/XMLSchema#string

Laurence Legros

http://www.w3.org/2001/XMLSchema#string

Marie Stève-Dumont

http://www.w3.org/2001/XMLSchema#string

Milou-Daniel Drici

http://www.w3.org/2001/XMLSchema#string

P2860

Prevalence of peripheral arterial disease and risk factors in persons aged 60 and older: data from the National Health and Nutrition Examination Survey 1999-2004.

A phase 2 trial of ponatinib in Philadelphia chromosome-positive leukemias

Early onset hypercholesterolemia induced by the 2nd-generation tyrosine kinase inhibitor nilotinib in patients with chronic phase-chronic myeloid leukemia.

Nilotinib versus imatinib for newly diagnosed chronic myeloid leukemia.

Rapid initial decline in BCR-ABL1 is associated with superior responses to second-line nilotinib in patients with chronic-phase chronic myeloid leukemia

First-line therapy for chronic myeloid leukemia: new horizons and an update.

Nilotinib is effective in patients with chronic myeloid leukemia in chronic phase after imatinib resistance or intolerance: 24-month follow-up results

Nilotinib is superior to imatinib as first-line therapy of chronic myeloid leukemia: the ENESTnd study.

[Prevalence and risk factors of peripheral arterial disease in an outpatient screening campaign].

Therapeutic drug monitoring of imatinib in chronic myeloid leukemia: experience from 1216 patients at a centralized laboratory.

P304

204-208

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1111/FCP.12102

http://www.w3.org/2001/XMLSchema#string

P433

2

http://www.w3.org/2001/XMLSchema#string

P478

29

http://www.w3.org/2001/XMLSchema#string

P577

2015-03-11T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

25619238

http://www.w3.org/2001/XMLSchema#string